Latest News and Press Releases

Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis KY1005 met both primary end points demonstrating: A clinically meaningful improvement in disease activity...

KYMAB WINS SUPREME COURT CASE AGAINST REGENERON Landmark UK Supreme Court Decision Invalidates Regeneron Patent Claims Cambridge, UK; 24 June, 2020: Kymab, a clinical-stage biopharmaceutical company...

Kymab announces that the US Patent Trial and Appeal Board rejects a fifthrequest by Regeneron for invalidation of Kymab’s US patents USPTO upholds a fifth Kymab patent covering Human Antibodies and...

Kymab announces that the US Patent Trial and Appeal Board rejects requests for invalidation filed by Regeneron USPTO upholds 4 Kymab patents covering Human Antibodies and Platforms Cambridge, UK:...

Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting KY1044 increases the ratio of intratumoral cytotoxic-to-regulatory T cells and induces tumor...

Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting Clinical trial initiated in February 2019 in the U.S., MD Anderson...

Kymab Appoints Pharmaceutical Veteran Simon Sturge as Chief Executive Officer Cambridge, UK; April 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics,...

Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases Top-line Phase I data demonstrated favorable safety, pharmacokinetics and...